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ABSTRACT
Background: Indonesia is an endemic country for hepatitis B viral infection. Thus, early diagnosis of cirrhosis 
is important to be established with regard to prompt treatment and to determine the patients’ prognosis. Liver 
biopsy which is a gold standard in diagnosing liver cirrhosis has several limitations, such as expensive and 
invasive. The objective of this study was to identify the accuracy of non-invasive markers: aspartate/alanine 
transaminase ratio (AAR), age-platelet index (API), aspartate transaminase to platelet ratio index (APRI), 
spleen to platelet ratio index (SPRI), and age-spleen-platelet ratio index (ASPRI) in predicting cirrhosis in 
chronic hepatitis B patients.
Methods: A diagnostic study was performed in Division of Hepatology and Hepatology Outpatient Clinic, 
Depatment of Internal Medicine, Cipto Mangunkusumo Hospital between January 2009 and July 2010, with the 
participation of 71 chronic hepatitis B patients who had undergone liver biopsy consecutively. Stage of fibrosis 
was determined based on the METAVIR scoring system. Five non-invasive markers: AAR, API, APRI, SPRI, and 
ASPRI were compared with liver biopsy results. Statistical analysis was performed by using T-test and Spearman 
correlation test using SPSS version 13.
Results: API, APRI, SPRI, and ASPRI had significant correlation with the incidence of liver cirrhosis in 
hepatitis B infection (p < 0.05). However, AAR had no correlation with the incidence of cirrhosis. Using the 
cut-off point of 1.19, APRI  was the best marker with area under curve (AUC) 0.91, sensitivity 83.3%, and 
specificity 89.2%.
Conclusion: Non-invasive markers were suitable in predicting cirrhosis and have the potential to decrease 
the number of liver biopsy in chronic hepatitis B patients.
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ABSTRAK
Latar belakang: Indonesia adalah negara endemis infeksi virus hepatitis B.Oleh sebab itu, diagnosis dini 
sirosis sangat penting dilakukan dalam hal tatalaksana dan penentuan prognosis dari pasien. Biopsi hati yang 
merupakan standar baku untuk menegakkan sirosis hati memiliki keterbatasan antara lain mahal dan bersifat 
invasif. Tujuan dari penelitian ini yaitu untuk mengetahui akurasi petanda non-invasif aspartate/alanine 
aminotransferase ratio (AAR), age-platelet index (API), aspartate aminotransferase to platelet ratio index 
(APRI), spleen to platelet ratio index (SPRI) dan age-spleen-platelet ratio index (ASPRI) untuk memprediksi 
sirosis pada pasien dengan hepatitis B kronik.
Metode: Penelitian ini merupakan penelitian uji diagnostik yang dilakukan di Divisi Hepatologi dan Poliklinik 
Hepatologi Ilmu Penyakit Dalam Rumah Sakit Cipto Mangunkusumo selama bulan Januari 2009 hingga Juli 
2010  dengan  melibatkan 71 pasien hepatitis B kronik yang telah melalui biopsi hati secara konsekutif. Stadium 
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fibrosis dinilai berdasarkan sistem skoring METAVIR. Lima petanda non invasif: AAR, API, APRI, SPRI dan 
ASPRI dibandingkan dengan hasil biopsi hati. Uji T dan uji korelasi Spearman digunakan dengan  analisis 
statistik program SPSS versi 13.
Hasil: API, APRI, SPRI dan ASPRI memiliki korelasi yang signifikan dengan kejadian sirosis pada infeksi 
hepatitis B (p < 0,05), namun petanda AAR tidak memiliki korelasi dengan kejadian sirosis. Menggunakan nilai 
batas 1,19, petanda APRI adalah petanda terbaik dengan luas area di bawah kurva 0,91, sensitifitas 83,3% 
dan spesifisitas 89,2%.
Kesimpulan: Petanda non-invasif dapat digunakan untuk prediksi sirosis dan dapat menurunkan angka 
biopsi hati pada pasien hepatitis B kronik.
Kata kunci: petanda non invasif, hepatitis B kronik, sirosis hati
INTRODUCTION
Hepatitis B virus (HBV) infection is the main 
etiology of acute and chronic liver disease worldwide, 
which will finally lead to cirrhosis and hepatocelullar 
carcinoma (hepatoma). Approximately 350 million 
people experienced chronic infection and between 
500,000 and 1.2 million death per year occurred due to 
hepatitis B associated complications.1 The prevalence 
of HBV infection in Indonesia and South East Asian 
countries was 10-20%, mostly acquired perinatally; 
while the prevalence of HBV infection in Jakarta was 
reported to be 4.1%.2,3,4 Therefore, liver cirrhosis is 
important to be detected early to slower the clinical 
progression of the disease’ and decrease the incidence 
of complication which may happen with antivirus 
administration.
Liver biopsy is the gold standard to diagnose 
liver cirrhosis and plays a part in the management 
of chronic hepatitis B infection. Consensus on 
management of hepatitis B in Indonesia 2006 stated 
that one of the criteria in antivirus administration was 
the presence of significant degree liver fibrosis.5 Liver 
biopsy also provides the information on the degree of 
necroinflammation activity and degree of liver fibrosis, 
which are required in determining the prognosis and 
also plays role in identifying other etiologies of liver 
disease.6,7 However, liver biopsy has some limitations, 
such as relatively high cost procedure, invasive, 
high morbidity and mortality risk (3% and 0.03%, 
respectively), also the bias potency due to sampling 
error and inter and intraobserver variation which may 
result in error in determining the degree of fibrosis.8 
Liver biopsy facility and histopathologic examination 
for liver tissue are not available evenly in Indonesia. In 
regard to the limitations of liver biopsy, a non-invasive 
method to diagnose liver cirrhosis is required.
Several reported serologic non-invasive markers 
can be used to predict fibrosis and cirrhosis in hepatitis 
C, includes aspartate aminotransferase (AST) to alanine 
aminotransferase (ALT) ratio (AAR), AST-to-platelet 
ratio index (APRI), and age-platelet count index 
(API).9 However, the use of non-invasive predictors 
for hepatitis C cannot be directly implemented in 
hepatitis B due to the presence of difference in natural 
progression of the disease, which is associated with 
different increase of ALT, and histopathological 
appearance.9,10 Therefore, the objective of this study 
was to know the accuracy degree of ASPRI, API, SPRI, 
AAR, and APRI in predicting cirrhosis non-invasively 
in chronic hepatitis B patients.
METHOD
A diagnostic test study was performed in 71 patients 
with chronic hepatitis B in Hepatology Outpatient Clinic, 
Internal Medicine Department, Cipto Mangunkusumo 
Hospital consecutively between January 2009 and July 
2010. Patients with chronic hepatitis B who agreed to 
participate in this study were included in the study after 
informed consent has been received. Blood examination, 
abdomen ultrasonography (USG), and liver biopsy 
were performed on the same day. Patients with signs 
of liver decompensation, such as ascites, history of 
hematemesis, hepatic encephalopathy, Child Pugh class 
B and C, coagulation disorder, suffered from chronic 
liver disease due to other etiologies, such as hepatitis C 
co-infection, under antiviral or hepatoprotector therapy, 
consuming alcohol, and suffered from other disease 
causing splenomegaly were not included in this study.
Liver tissue was examined by an anatomy 
pathologist. Liver fibrosis was determined by using 
METAVIR criteria, which constitute of no fibrosis 
found (F0), portal fibrosis without septa (F1), portal 
fibrosis with septa (F2), many septa without fibrosis 
(F3), and liver cirrhosis (F4). Meanwhile, blood 
examination and liver biopsy were performed on 
the same day. Spleen size was measured by using 
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ultrasonography (USG) by a hepatologist. The longest 
longitudinal diameter is measured by using electronic 
measurer in USG monitor. Markers AAR, API, APRI, 
SPRI, and ASPRI were calculated from the laboratory 
examination data, age, and spleen USG (Table 1).
SPSS version 13 software was used in statistical 
analysis of this study. Relationship between these five 
non-invasive markers: AAR, API, SPRI, APRI, and 
ASPRI with cirrhosis were analyzed using T-test. P 
value < 0.05 was assumed as statistically significant. 
Regression analysis (Spearman correlation test) was 
conducted to evaluate if those variables were correlated 
with the presence of cirrhosis. To know the accuracy 
of variable prediction, receiver operating characteristic 
(ROC) curve analysis was performed. Difference 
between areas under ROC curve was used to compare 
prediction capability of each non-invasive marker. Cut 
off value was set in the highest point of sum value of 
sensitivity and specificity.
RESULTS
Patients’ clinical and laboratory data were detailed 
in Table 2. Total analyzed patients were 71 patients, 
with oldest age group was 40-49 years old. The median 
value of AST was 61.86 and the median value of ALT 
Table 1. Definition of non-invasive markers
Non invasive mark Definition Pattern
AAR AST/ALT ratio index AST/ALT
API Age platelet index Age (years): 
< 30 = 0; 30-39 = 1; 40-49 = 2; 50-59 = 3; 60-69 = 4; > 70 = 5
Thrombocyte count (109/L): 
> 225 = 0; 200-224 = 1; 175-199 = 2; 150-174 = 3; 125-149 = 4; < 125 = 5
API is a sum value of age and thrombocyte count
APRI AST to platelet ratio index [(AST/ULN)/thrombocytes count (109/L)] x 100
SPRI Spleen to platelet ratio index Spleen size (cm)/thrombocyte count (109/L) x 100
ASPRI Age spleen to platelet ratio 
index
Age (years): <  30 = 0; 30-39 = 1; 40-49 = 2; 50-59 = 3; 60-69 = 4; > 70 = 5
ASPRI is a sum value of age and SPRI
AST: aspartate transaminase; ALT: alanine aminotransferase; ULN: upper limit of normal
Table 2. Patients’ characteristics
Characteristic Results
Sex (%)
Male
Female 
Age (years)
< 30
30-39
40-49
50-59
60-69
BMI (kg/m2)
AST (mg/dL)
ALT (mg/dL)
Platelet (109/L)
Albumin (mg/dL)
Globulin (mg/dL)
Spleen (cm)
Fibrosis degree
F0 Metavir
F1 Metavir
F2 Metavir
F3 Metavir
F4 Metavir
55 
45
20–68 years
11 (15.5%)
16 (22.5%)
24 (33.8%)
12 (16.9%)
8 (11.3%)
23.07 (16.6–31.7)
61.86 (18–608)
69.99 (13–849)
247 (88-448) 
4.2 (2.7-4.7) 
3.12 (2.3-4.2) 
9.95 (5.92-13.54)
1 (1.4%)
30 (42.3%)
28 (39.4%)
6 (8.5%)
6 (8.5%)
BMI: body mass index; AST: aspartate transaminase; ALT: alanine 
aminotransaminase
Table 3. Univariate analysis of variable and non-invasive markers to liver cirrhosis 
Variable Without cirrhosis
n=65
With cirrhosis
n=6
p*
Age  (years) 42.49 ± 11.91 50.17 ± 11.51 0.17
AST (mg/dL) 29 (18-361) 86.5 (43-608) 0.001
ALT (mg/dL) 29 (13-557) 108.5 (41-849) 0.003
Spleen (cm) 10.11 (5.92-12.95) 11.30 (9.23-13.54) 0.037
Platelets (x109/L) 255.0  ± 73.0 161.0  ± 38.0 0.001
AAR 0.96 (0.45-1.95) 0.93 (0.66-1.51) 0.788
API 2 (0-8) 6 (2-7) 0.005
APRI 0.3 (0.12-7.4) 1.47 (0.56-7.58) 0.01
SPRI 4 (1.99-13.6) 7.12 (5.04-12.09) 0.02
ASPRI
HBV-DNA 0 (> 20,000 UI/mL)
6.02 (2.24-16.6)
55.7%
9.65 (6.03-14.09)
66.7%
0.03
0.287
AST: aspartate transaminase;ALT: alanine aminotransaminase;AAR: AST/ALT ratio index; API: age platelet index;APRI: AST to platelet ratio 
inex; SPRI: spleen to platelet ratio index; ASPRI: age spleen to platelet ratio index;HBV-DNA: hepatitis B virus- deoxyribonucleic acid;*T-test
was 69.99. Based on degree of fibrosis, most patients 
were in the F1 group.
Analysis to variables associated to cirrhosis showed 
that there was significant difference between cirrhosis 
and non-cirrhosis group in all analyzed variables (AST, 
ALT, spleen size, thrombocyte level, API, APRI, SPRI, 
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and ASPRI), except age, AAR, and HBV-DNA (Table 
3). In the five non-invasive markers being analyzed, 
there was significant correlation with the incidence of 
cirrhosis, except for marker AAR elaborated in Table 4.
DISCUSSION
This study was an initial study with total sample 
not as big as previous studies and proportion of 
fibrosis group was less evenly distributed (F4: 8,5%). 
Correlation analysis between few single variables 
and non-invasive markers with incidence of cirrhosis 
showed that AST, ALT, thrombocyte level, spleen 
size and all non-invasive markers, except AAR had 
signficant difference statistically between cirrhosis and 
non-cirrhosis group (p < 0.05). These findings were 
similar to prospective study results in 125 chronic 
hepatitis B patients performed by Lee et al, which 
reported that AST, ALT, platelet, API, and APRI had 
significant difference between cirrhosis and non-
cirrhosis group.11
Analysis to association of age variable and AAR 
marker and HBV-DNA revealed no significant 
difference between cirrhosis and non-cirrhosis group. 
Clinical progression of hepatitis B is different from 
hepatitis C, in which progressive inflammation 
happens persistently until liver cirrhosis is formed. 
Differently, the clinical progression of hepatitis B is 
oftenly accompanied with acute exacerbation, marked 
by the elevation of AST more to ALT, and followed by 
inactive period. This explains why age and comparison 
of AAR were not significantly different between 
cirrhosis and non-cirrhosis group.10
Thrombocyte level and spleen size are significant 
predictors to the incidence of cirrhosis. Splenomegaly 
is a sign occurred due to elevation in portal circulation 
pressure, causing red pulp spleen congestion. Size 
of the spleen is the clinical characteristic in chronic 
liver disease. Study by Aube et al reported that spleen 
size was associated with portal hypertension due 
to fibrosis in the liver.12 Thrombocytopenia is one 
of the liver cirrhosis markers which is caused by 
thrombopoetin deficiency (TPO). A study showed that 
there was increase of TPO level and peripheral blood 
Table 4. Correlation of non-invasive markers with liver cirrhosis
Variable Coefficient correlation(Spearman’s rho) p*
AAR -0.032 0.79
API 0.334 0.004
APRI 0.395 0.001
SPRI 0.368 0.002
ASPRI 0.356 0.002
AAR: AST/ALT ratio index; API: age platelet index; APRI: AST to platelet ratio 
index; SPRI: spleen to platelet ratio index; ASPRI: age spleen to platelet ratio 
index; *Spearman correlation test
ROC curve was prepared to evaluate diagnosis 
accuracy from those five non-invasive markers in 
predicting the incidence of liver cirrhosis (Figure 1). 
Area under the curve (AUC) value to differentiate F4 
and F0-F3 from AAR was 0.467 (95% CI = 0.232-
0.702). AUC value from API, APRI, SPRI, and ASPRI 
were 0.842 (95% CI = 0.658-1.000), 0.910 (95% CI 
= 0.836-0.985), 0.882 (95% CI = 0.792-0.972), and 
0.869 (95% CI = 0.743-0.996), respectively. Based on 
the area of AUC from the five non-invasive markers 
being analyzed, AAR has the worst accuracy and APRI 
has the best accuracy.
 
Figure 1. Receiver operating curve (ROC) of five non-invasive 
markers to predict liver cirrhosis
Table 5 revealed the cut off value of those five 
non-invasive markers, including their sensitivity, 
specificity, positive predictive value (PPV), negative 
predictive value (NPV), positive likelihood ratio 
(LLR+), and negative likelihood ratio (LLR-) to predict 
liver cirrhosis.
Table 5. Accuracy diagnosis of non-invasive markers to predict 
liver cirrhosis (F4)
Non-
invasive 
marker
Cut-
off
point
Cirrhosis (%)
Sensi-
tivity
Speci-
ficity
PPV NPV LLR+ LLR-
AAR 0.65 100 81.5 10.1 100 1.22 0
API 4.5 83.3 83.1 31 98 4.93 0.20
APRI 1.19 83.3 89.2 38 98 7.71 0.19
SPRI 5.74 83.3 81.5 29 98 4.50 0.20
ASPRI 8.74 83.3 86.2 35 98 6.03 0.19
AAR: AST/ALT ratio index; API: age platelet index;APRI: AST to platelet ratio 
index; SPRI: spleen to platelet ratio index; ASPRI: age spleen to platelet ratio 
index; PPV: positive predictor value; NPV: negative predictor value; LLR+: 
positive likelihood ratio; LLR-: negative likelihood ratio
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thrombocytes in liver cirrhosis patients after underwent 
liver transplantation. This proved the role of TPO in 
the pathophysiology of thrombocytopenia in liver 
cirrhosis.13 Thrombocyte count is the simplest marker 
to evaluate liver fibrosis. Decreased thrombocyte 
count is moderately correlated with the histopathology 
of fibrosis with correlation coefficient of 0.46-0.5, 
sensitivity of 77%, and specificity of 88%.14
Analysis between non-invasive markers and 
incidence of cirrhosis revealed that besides AAR, other 
markers had significant correlation with cirrhosis. 
APRI marker had the strongest correlation, followed by 
marker SPRI, ASPRI, and API (Spearman’s rho 0.395, 
0.368, 0.356 and 0.334 with p < 0.05). This result is 
different from the study conducted by Kim et al, which 
found out that those five non-invasive markers were 
correlated with cirrhosis and ASPRI had the strongest 
correlation.9 However, the result of retrospective study 
by Yilmaj et al in patients with chronic hepatitis B, 
chronic hepatitis C, and non-alcoholic fatty liver, 
exhibited that APRI showed higher accuracy in 
determining liver fibrosis in chronic hepatitis C patients 
compared to chronic hepatitis B patients.15
With the cut off value of 0.65, AAR marker 
showed best results with sensitivity 100%, specificity 
18,5%, AUC 0.467, PPV 10.1%, NPV 100%, positive 
likelihood ratio 1.22 and negative likelihood ratio 0. 
Based on those values, it could be interpreted that AAR 
has low AUC and does not provide any additional 
information in the diagnosis of liver cirrhosis. 
Elevation of AST in advanced liver fibrosis is caused by 
decreased AST clearance and mitochondria destruction 
which leads to relative elevation of AST compared to 
ALT. However, chronic hepatitis B infection is oftenly 
accompanied with acute exacerbation, marked by 
more elevated AST compared to AST. Thus, the AST/
ALT ratio could not be used as an accurate marker 
in predicting liver cirrhosis in chronic hepatitis B 
infection.
In API marker, using the cut off value of 4.5 
best results were obtained, with sensitivity 83.3%, 
specificity 83.1%, AUC 0.842, PPV 31%, NPV 98%, 
positive likelihood ratio 4.93, and negative likelihood 
ratio 0.20. Based on those values, it could be interpreted 
that API had good AUC, and patient with F4 had 4.93 
higher possibility to give value > 4.5 compared to 
patients with F0-F3. Probability of patients with F4 to 
get value < 4.5 is 0.2 compared to patients with F0-F3. 
In APRI marker, using cut off value of 1.19, best 
results were obtained with sensitivity 83.3%, specificity 
89.2%, AUC 0.91, PPV 38%, NPV 98%, positive LLR 
7.71, and negative LLR 0.19. Based on these values, 
it could be interpreted that APRI had highest and best 
AUC among other non-invasive markers. Patients with 
F4 had 7.71 times higher possibility to give value > 
1.19 compared to patients with F0-F3. The possibility 
of patients with F4 to have value < 1.19 is 0.19 times 
compared to patients with F0-F3.
In SPRI marker, using the cut off value 5.74, best 
results were obtained with sensitivity 83.3%, specificity 
81.5%, AUC 0.882, PPV 29%, NPV 98%, positive 
LRR 4.5, and negative LRR 0.2. Based on these values, 
it could be interpreted that SPRI had good AUC, and 
patients with F4 had 4.5 times higher possibility to give 
out value of > 5.74 compared to patients with F0-F3. 
The possibility of patients with F4 to get value < 5.74 
was 0.2 times compared to patients with F0-F3. The 
accuracy of SPRI was the lowest compared to the other 
four analyzed non-invasive markers.
In ASPRI marker, best results of non-invasive 
markers predicting F4 was obtained using the cut 
off value of 8.74, with sensitivity 83.3%, specificity 
86.2%, AUC 0.869, PPV 35%, NPV 98%, positive 
LLR 6.03, and negative LLR 0.19. Based on these 
values, it could be interpreted that ASPRI had the best 
AUC, and F4 patients had 6 times higher possibility 
to give value > 8.74 compared to F0-F3 patients. The 
possibility of F4 patient to give value < 8.74 was 0.2 
times compared to F0-F3 patients.
Study on non-invasive markers to predict cirrhosis 
in hepatitis B which was conducted by Kim et al in 
Korea, showed that formula such as ASPRI, API, SPRI 
could be used to predict or exclude the incidence of 
cirrhosis with quite high accuracy.9 Kim et al, revealed 
that from those five non-invasive markers, APRI had 
the worst accuracy with AUC under 0.8 and ASPRI 
was the best marker with AUC 0.908. Differently, in 
this study, APRI was the best non-invasive markers 
from those five non-invasive markers with AUC 0.91 
and AAR was the worst marker with AUC 0.467 and 
could not be used to evaluate liver cirrhosis.9
PPV values in those further analyzed four invasive 
markers were low, though it has quite high specificity 
for each cut off point. This was because PPV was a 
post-test probability influenced by low prevalence of 
F4 (pretest probability), specifically 8%.
 Result of this study is different with the study 
conducted by Kim et al and Wai et al, particularly for 
marker AAR and APRI. This was because of some 
reasons, such as this study was an introduction study 
with lesser participants compared to the other two 
previous studies; other difference could be caused 
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by the previous use of hepatoprotector. Furthermore, 
studies by Kim et al and Wai et al were performed 
retroscpectively and thus, the use of hepatoprotector 
could not be eliminated; while in this study there was 
wash out period of 2 weeks before the study.9.16 Use 
of hepatoprotector may alter the transaminase enzyme 
level which could affect markers AAR and APRI. Other 
difference which could have influenced the result of 
the study was the profile age of the subjects, in which 
the age of the subjects in this study is older compared 
to the subjects in the study of Kim et al.9 Age affects 
the clinical progression, in which there was higher 
incidence of acute exacerbations in younger age.
CONCLUSION
Based on the analysis of this study, it can be 
concluded that non-invasive markers give out good 
result to be used as exclusion tests to exclude cirrhosis 
because of its high sensitivity and NPV value. As a 
diagnostic tool of cirrhosis, non-invasive markers still 
has limitations, because of the low PPV value as an 
effect of low prevalence of cirrhosis among chronic 
hepatitis B patients.
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